Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | GBIO | Stock Option (right to buy) | Feb 10, 2022 | Common Stock | 105K | $4.59 | Direct | F1 | ||||||
holding | GBIO | Stock Option (right to buy) | Feb 10, 2022 | Common Stock | 14.2K | $5.16 | Direct | F2 | ||||||
holding | GBIO | Stock Option (right to buy) | Feb 10, 2022 | Common Stock | 14.2K | $5.16 | Direct | F3 | ||||||
holding | GBIO | Stock Option (right to buy) | Feb 10, 2022 | Common Stock | 53.8K | $5.16 | Direct | F4 | ||||||
holding | GBIO | Stock Option (right to buy) | Feb 10, 2022 | Common Stock | 31.5K | $30.25 | Direct | F5 | ||||||
holding | GBIO | Stock Option (right to buy) | Feb 10, 2022 | Common Stock | 66K | $6.49 | Direct | F6 | ||||||
holding | GBIO | Restricted Stock Units | Feb 10, 2022 | Common Stock | 33K | Direct | F7, F8 |
Id | Content |
---|---|
F1 | The option to purchase 113,230 shares was granted on December 6, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on October 1, 2019 and the remaining shares vesting in equal quarterly installments thereafter. |
F2 | The option to purchase 14,153 shares was granted on March 5, 2020. The shares underlying the option vest in full upon the date on which the Board of Directors of the Issuer determines that the Issuer has dosed the initial patient in its first clinical trial, provided that such event occurs on or before July 1, 2023. |
F3 | The option to purchase 14,153 shares was granted on March 5, 2020. The shares underlying the option vest over four years, with 25% of the shares vested on March 5, 2021 and the remaining shares vesting in equal quarterly installments thereafter. |
F4 | The option to purchase 53,784 shares of common stock was granted on March 5, 2020. The shares underlying the option vest over four years, with 25% of the shares vested on February 1, 2021 and the remaining shares vesting in equal quarterly installments thereafter. |
F5 | The option to purchase 31,500 shares of common stock was granted on January 22, 2021. The shares underlying the option vest over four years, with 25% of the shares vested on January 22, 2022 and the remaining shares vesting in equal quarterly installments thereafter. |
F6 | The option to purchase 66,000 shares of common stock was granted on January 21, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on January 21, 2023 and the remaining shares vesting in equal quarterly installments thereafter. |
F7 | The shares underlying the restricted stock units vest over two years, with 25% of the shares vesting on July 15, 2022 and the remaining shares vesting in equal quarterly installments thereafter. |
F8 | Each restricted stock unit represents the right to receive one share of the company's common stock. |